Program
Cyclosporine
Also written as “cyclosporine”, “Cyclosporine A” and “Ciclosporin”.
Its studies are mostly in Dry Eye Syndromes · Dermatitis, Atopic · Bronchiolitis Obliterans Syndrome · Conjunctivitis, Allergic · Bronchiolitis Obliterans, led by 26 companies.
Drug pageCyclosporine: every studyMany companies study it; this page follows only the 81 they lead. All 388 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 220 open or running | phase 4since Sep 6, 2005 | Sep 6, 2005 | none ahead |
| Pfizerits history only | 80 open or running | phase 4since Sep 13, 2005 | Jun 30, 2004 | none ahead |
| Hoffmann-La Rocheits history only | 70 open or running | phase 4since Jun 30, 2005 | Jun 30, 2005 | none ahead |
| Santen Pharmaceuticalits history only | 50 open or running | phase 3since May 19, 2006 | May 19, 2006 | none ahead |
| AbbVieits history only | 40 open or running | phase 4since Apr 22, 2014 | Apr 17, 2009 | none ahead |
| Zambon SpA | 40 open or running | phase 3since Aug 30, 2018 | Aug 30, 2018 | none ahead |
| Sirion Therapeuticsits history only | 30 open or running | phase 3since Jul 13, 2007 | Jul 13, 2007 | none ahead |
| Amsterdam Molecular Therapeuticsits history only | 20 open or running | phase 3since Apr 30, 2009 | Apr 30, 2009 | none ahead |
| APT Pharmaceuticalsits history only | 20 open or running | phase 3since Sep 17, 2008 | Sep 17, 2008 | none ahead |
| Hanlim Pharm.its history only | 20 open or running | phase 3since Dec 10, 2012 | Dec 10, 2012 | none ahead |
| Innovative Medicalits history only | 20 open or running | phase 4since Jul 5, 2006 | Jul 5, 2006 | none ahead |
| Novaliqits history only | 20 open or running | phase 4since Mar 19, 2024 | Nov 25, 2015 | none ahead |
| Perle Bioscienceits history only | 20 open or running | phase 3since Jan 2, 2013 | Jan 2, 2013 | none ahead |
| Research Insightits history only | 20 open or running | phase 4since Apr 6, 2020 | Apr 6, 2020 | none ahead |
| Sigmoid Pharmaits history only | 20 open or running | phase 2since Dec 15, 2009 | Dec 15, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 4since Apr 8, 2020 | Feb 13, 2016 | none ahead |
| Fovea Pharmaceuticalsits history only | 10 open or running | phase 2since Apr 29, 2010 | Apr 29, 2010 | none ahead |
| ISDINits history only | 10 open or running | phase 2since Dec 20, 2007 | Dec 20, 2007 | none ahead |
| LEO Pharmaits history only | 10 open or running | phase 4since Oct 16, 2018 | Oct 16, 2018 | none ahead |
| Pari Pharmaits history only | 10 open or running | phase 3since Apr 11, 2011 | Apr 11, 2011 | none ahead |
| PerioCits history only | 10 open or running | phase 2since Feb 12, 2015 | Feb 12, 2015 | none ahead |
| Pharming Groupits history only | 10 open or running | phase 1since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| Spherium Biomedits history only | 10 open or running | phase 2since Aug 4, 2016 | Aug 4, 2016 | none ahead |
| Sublimity Therapeutics Holdcoits history only | 10 open or running | phase 2since Jan 31, 2019 | Jan 31, 2019 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceuticalits history only | 11 open or running | phase 3since Jan 3, 2025 | Jan 3, 2025 | none ahead |
Also a collaborator on its studies: Parexel, Dr. Falk Pharma, Syreon and The Clinical Trial.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Zambon SpA only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 30, 2018First studies: 2 phase 3 studies in Bronchiolitis ObliteransFirst studyNCT03657342, NCT03656926
- Jul 19, 2019Phase 3 study in Bronchiolitis ObliteransNCT04039347 · 164 enrolled · United States, Austria, Belgium and more
- Sep 25, 2019Phase 2 study in Bronchiolitis Obliterans SyndromeNCT04107675 · 6 enrolled · France, Germany, Spain
TargetBeta
“Cyclophilin A modulator”ChEMBL 37, by rule
Studies
All 4 Zambon SpA leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04107675Bronchiolitis Obliterans Syndrome · France, Germany, Spain | 2 | Terminated | Jun 16, 2022 | 6 |
| NCT04039347Bronchiolitis Obliterans · United States, Austria, Belgium and more | 3 | Terminated | Feb 25, 2026 | 164 |
| NCT03657342Bronchiolitis Obliterans · United States, Belgium, France and more | 3 | Completed | Apr 16, 2024 | 62 |
| NCT03656926Bronchiolitis Obliterans · United States, Austria, Belgium and more | 3 | Completed | Mar 12, 2024 | 169 |
How it is read
Names in the registry
- “cyclosporine”, 12 entries
- “Cyclosporine”, 10 entries
- “Cyclosporine A”, 6 entries
- “Ciclosporin”, 4 entries
- “Liposomal Cyclosporine A”, 3 entries
Codes read as this program: NOVA22007.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 15 studies
- Dermatitis, Atopic, 5 studies
- Bronchiolitis Obliterans Syndrome, 4 studies
- Conjunctivitis, Allergic, 4 studies
- Bronchiolitis Obliterans, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.